NCT00371488View on ClinicalTrials.gov

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 6, 2006

Primary Completion Date

December 10, 2007

Study Completion Date

December 10, 2007

Conditions
Neoplasms, Breast
Interventions
DRUG

GW572016 oral tablets

Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.

Trial Locations (2)

350-1298

GSK Investigational Site, Saitama

135-8550

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY